Basit öğe kaydını göster

Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod [Meeting Abstract]

dc.contributor.authorFragoso, Y. D.
dc.contributor.authorAlroughani, R.
dc.contributor.authorBarnett, M.
dc.contributor.authorBrooks, J. B.
dc.contributor.authorButzkueven, H.
dc.contributor.authorBoz, C.
dc.contributor.authorTicha, V.
dc.date.accessioned2020-06-21T13:32:03Z
dc.date.available2020-06-21T13:32:03Z
dc.date.issued2016
dc.identifier.issn1352-4585
dc.identifier.issn1477-0970
dc.identifier.urihttps://hdl.handle.net/20.500.12712/13100
dc.description32nd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) -- SEP 14-17, 2016 -- London, ENGLANDen_US
dc.descriptionHavrdova, Eva Kubala/0000-0002-9543-4359; Lugaresi, Alessandra/0000-0003-2902-5589en_US
dc.descriptionWOS: 000383267201435en_US
dc.description.abstract…en_US
dc.description.sponsorshipEuropean Comm Treatment & Res Multiple Sclerosisen_US
dc.description.sponsorshipBiogen-IdecBiogen; Merck-SeronoMerck SeronoMerck & Company; NovartisNovartis; GenzymeGenzyme Corporation; BiogenBiogen; MerckMerck & Company; Oxford PharmaGenesis; Biogen IdecBiogen; Merck SeronoMerck SeronoMerck & Company; Almirall; BayerBayer AG; SanofiSanofi-Aventis; Teva; Fondazione Italiana Sclerosi MultiplaFondazione Italiana Sclerosi Multipla (FISM); Biogen IncBiogen; Bayer-ScheringBayer AGen_US
dc.description.sponsorshipMichael Barnett has served on scientific advisory boards for Biogen-Idec, Novartis and Genzyme and has received conference travel support from Biogen-Idec and Novartis. His institution has received research support from Biogen-Idec, Merck-Serono and Novartis.; Helmut Butzkueven has received consulting fees from Genzyme, Biogen, Novartis, Merck and Oxford PharmaGenesis; and grant/ research support from Biogen, Novartis, Merck and Genzyme Cavit Boz has nothing to disclose; Franco Granella has served on scientific advisory boards for Biogen Idec, Novartis and Sanofi Aventis and has received funding for travel and speaker honoraria from Biogen Idec, Merck Serono, and Almirall; Alessandra Lugaresi has served as a Bayer, Biogen, Merck Serono, Novartis and Genzyme Advisory Board Member. She received travel grants and honoraria from Bayer, Biogen, Merck Serono, Novartis, Sanofi, Teva and Fondazione Italiana Sclerosi Multipla and research grants for her Institution from Bayer, Biogen, Merck Serono, Novartis, Sanofi, Teva and Fondazione Italiana Sclerosi Multipla.; Tim Spelman received compensation for serving on scientific advisory boards, honoraria for consultancy and funding for travel from Biogen Inc; speaker honoraria from Novartis.; Murat Terzi received travel grants from Merck Serono, Novartis, Bayer-Schering, Merck-Serono and Teva; has participated in clinical trials by Sanofi Aventis, Roche and Novartis.en_US
dc.language.isoengen_US
dc.publisherSage Publications Ltden_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.titleLymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod [Meeting Abstract]en_US
dc.typeconferenceObjecten_US
dc.contributor.departmentOMÜen_US
dc.identifier.volume22en_US
dc.identifier.startpage337en_US
dc.identifier.endpage338en_US
dc.relation.journalMultiple Sclerosis Journalen_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster